Argo Biopharma announced that the company has closed series A financing of US $63 million. This round of financing was led by Loyal Valley Capital, and co-invested by CPE fund, TAO CAPITAL, Trinity Fund, GSR United Capital. They are all well-known institutions in the industry. The primary goals of this funding are to advance the IND application of cardiovascular disease and rare disease pipelines, promote the identification of preclinical candidate drug molecules (PCCs) in multiple pipelines including hepatitis B, autoimmune system diseases, and neurological diseases, and the construction of R&D center and team establishment.

Argo Biopharma was established in 2021, focusing on the development of siRNA drugs, and was founded by several returnee scientists with rich experience in siRNA drug development. The company is dedicated to developing a new generation of siRNA drugs to provide better treatments for patients around the world.

Argo Biopharma has actively promoted multiple preclinical R&D pipelines since its founding. As of right now, several pipelines are in the IND-enabling stage, and it is anticipated that there will be multiple clinical phase 1 pipelines by 2023.